Lugano, Switzerland – Immunotherapy, which works by enabling the body’s immune system to recognise and destroy cancer cells improves long-term overall survival in patients with advanced melanoma in results from large international studies reported at ESMO 2024. (1,2) Researchers leading the longest follow-up study to date suggest that immunotherapy offers the potential for cure in patients who respond to this treatment. (1) Further clinical trials reported at ESMO 2024 show improved long-term survival with immunotherapy given before and after surgery in women with early-stage, hard-to-treat breast cancer (triple negative breast cancer) and in patients with muscle-invasive bladder cancer. (3,4)
“The main message from all of these studies is that immunotherapy continues to keep its promise and hope of long-term survival for many patients with different types of cancer,” said Dr Alessandra Curioni-Fontecedro, professor of oncology at the University of Fribourg and director of oncology at the Hospital of Fribourg, Switzerland, not involved in the study. “At ESMO 2024 we are seeing many studies in many different cancers showing that immunotherapy can work for a long time.”
Results of a phase 3 trial of immunotherapy with an anti–programmed death (PD)-1–based therapy showed continued long-term survival benefit in patients with advanced melanoma. (1) After follow-up of at least 10 years, the median overall survival was 71.9 months (about 6 years) in patients randomised to combination immunotherapy with nivolumab plus ipilimumab in the CheckMate 067 trial. Very few of the patients showing good initial response to anti-PD-1-based immunotherapy, with no disease progression for at least 3 years, had died of melanoma at 10 years (10-year melanoma specific survival rate 96%). The researchers suggested that there is now a potential for cure in patients responsive to these treatments.
“The results from this trial do confirm the potential for cure with immunotherapy in patients with advanced melanoma,” agreed Dr Marco Donia, associate professor of clinical oncology at the National Center for Cancer Immune Therapy of Denmark, Copenhagen University Hospital Herlev, Denmark, who was not a study author either. He added: “For patients who show no disease progression beyond three years, these longer-term results demonstrate that most of them never progress. The melanoma-specific survival is very high in this group of patients.”
“Importantly, the long-term survival benefit with immunotherapy is also seen in routine clinical practice, outside clinical trials,” Donia continued. “Immunotherapy has transformed advanced melanoma from something that was previously a deadly disease with a median survival of less than one year to what we see today, with half of patients surviving for many years.” He considered this raises practical questions about how best to follow these patients up, including whether they need long-term check-ups. “It also supports their right ‘to be forgotten’ as former cancer patients after five years of being cancer-free following the end of treatment, so they don’t suffer discrimination compared to the general population when seeking financial credit.”
Improved overall survival with immunotherapy was also reported in early-stage triple negative breast cancer (TNBC) and in muscle-invasive bladder cancer. Triple negative breast cancers are particularly difficult to treat because they do not have oestrogen or progesterone receptors or raised HER2 levels, so fail to respond to commonly used breast cancer treatments. Results showed a statically significant and clinically meaningful improvement in overall survival with immunotherapy plus chemotherapy before surgery and continued immunotherapy after surgery; the five-year overall survival rate was 86.6% in patients given immunotherapy and 81.2% in the placebo group. (3)
“This study shows improvements with immunotherapy in patients with the most aggressive subtype of breast cancer, where previously we could only offer chemotherapy,” said Curioni-Fontecedro. “We had thought that breast cancer may not be sensitive to immunotherapy alone but giving it in combination with chemotherapy before surgery and then further afterwards improves overall survival in many patients. The finding suggests the possibility that the combination of treatments might lead to a sensitisation of TNBC to immunotherapy.”
A similar improvement in overall survival with giving immunotherapy before surgery was seen in a study of patients with muscle-invasive bladder cancer. The Phase-3 NIAGARA study randomised patients to immunotherapy with durvalumab plus chemotherapy before radical cystectomy followed by continued immunotherapy or to only chemotherapy before surgery. Patients treated with immunotherapy showed significantly longer event-free survival (hazard ratio 0.68 [95% confidence interval 0.56-0.82] p<0.001) and overall survival (hazard ratio 0.75 [95% CI 0.59-0.93] p=0.0106) compared to those receiving chemotherapy alone.(4) The researchers noted that giving immunotherapy before surgery did not compromise the ability to perform radical cystectomy, which was completed in 88% of the immunotherapy group and 83% of the comparator arm.
Looking to the future of research with immunotherapy, Curioni-Fontecedro suggested: “We still have some major questions that are unanswered. The first is understanding why cancers recur in some patients despite initial response to immunotherapy. We still don’t understand how resistance to immunotherapy can occur in some patients. We need to understand what happens in these patients, what are the mechanisms of resistance and how we can overcome them.” She suggested that it is important that clinical researchers and pharmaceutical companies all work together to approach the issue of resistance to immunotherapy effectively. “As long as the issue of resistance is investigated in isolation, looking at individual immunotherapy agents, it will not be enough. We should all put our forces together to improve understanding and promote better treatment for the future.”
Notes to Editors
Please make sure to use the official name of the meeting in your reports: ESMO 2024 and the official congress hashtag: #ESMO24. Follow it to stay up to date and use it to take part in the conversation on X (Twitter), LinkedIn, Instagram, Facebook.
Disclaimer
This press release contains information provided by the author of the highlighted abstract and reflects the content of this abstract. It does not necessarily reflect the views or opinions of ESMO who cannot be held responsible for the accuracy of the data. Commentators quoted in the press release are required to comply with the ESMO Declaration of Interests policy and the ESMO Code of Conduct.
References
- Larkin J, Chiarion Sileni V, Gaudy Marqueste C et al. 10-y survival outcomes from the phase 3 CheckMate 067 trial of nivolumab plus ipilimumab in advanced melanoma. LBA43, presented at the ESMO Congress 2024 (13-17 September), Mini Oral Session on Sunday, 15 September, 14:45-16:25 (CEST) in the Oviedo Auditorium - Hall 3.
- Robert C, Carlino MS, McNeil C et al. Pembrolizumab vs ipilimumab in advanced melanoma: 10-year follow-up of the phase 3 KEYNOTE-006 study. LBA44, presented at the ESMO Congress 2024 (13-17 September), Mini Oral Session on Sunday, 15 September, 14:45-16:25 (CEST) in the Oviedo Auditorium - Hall 3.
- Schmid P, Cortes J, Dent RA et al. Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: overall survival results from the phase 3 KEYNOTE-522 study. LBA4, presented at the ESMO Congress 2024 (13-17 September), Presidential Symposium 2 on Sunday, 15 September, 16:30-17:50 (CEST) in the Barcelona Auditorium - Hall 2.
- Powles TB, van der Heijden MS, Galsky MD. A randomized phase 3 trial of neoadjuvant durvalumab plus chemotherapy followed by radical cystectomy and adjuvant durvalumab in muscle-invasive bladder cancer (NIAGARA). LBA5, presented at the ESMO Congress 2024 (13-17 September), Presidential Symposium 2 on Sunday, 15 September, 16:30-17:50 (CEST) in the Barcelona Auditorium - Hall 2.